Free Trial
→ Federal Reserve Reveals Disturbing New Plan To Control Your Money (From Weiss Ratings) (Ad)tc pixel
NASDAQ:INCY

Incyte Q3 2026 Earnings Date & Estimates

Incyte logo
$112.79 +0.04 (+0.04%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$113.30 +0.50 (+0.45%)
As of 10/9/2026 07:35 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Incyte is scheduled to report Q3 2026 earnings on Thursday, October 29, 2026, before market opens. The conference call is scheduled for 8:00 AM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Conference Call
8:00 AM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Incyte in Q3 2026

Incyte is expected to post earnings of -$3.20 per share on revenue of $1.47 billion. In the same quarter a year earlier Incyte reported $2.26 per share on revenue of $1.37 billion. Incyte last reported on July 28, 2026, posting $3.09 per share and beating the $2.15 consensus estimate. Incyte has beaten the consensus EPS estimate in 4 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$3.20
Expected Revenue
$1.47 billion
Prior-Year EPS
$2.26
Prior-Year Revenue
$1.37 billion
Expected EPS Growth
-241.6%
Expected Revenue Growth
+7.8%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
$3.09 (Beat by +$0.94)
Last Quarter Revenue
$1.67 billion
EPS Beat Rate
4 of last 8 quarters

Prepare for the Q3 2026 Call

Incyte Q3 2026 Earnings FAQ

Incyte (NASDAQ:INCY) is scheduled to report Q3 2026 earnings on Thursday, October 29, 2026, before market opens.

Incyte's Q3 2026 earnings conference call is scheduled for Thursday, October 29, 2026 at 8:00 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Incyte to post earnings of -$3.20 per share for Q3 2026.

The consensus revenue estimate for Incyte is $1.47 billion for Q3 2026.

Incyte Earnings Headlines

Incyte (NASDAQ:INCY) Rating Lowered to Hold at Wall Street Zen
 |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31104296
Incyte’s Latest Dermal PK Study: What Completed Early-Stage Data Mean for INCY Investors
October 9 at 12:51 PM  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/incytes-latest-dermal-pk-study-what-completed-early-stage-data-mean-for-incy-investors?utm_source=marketbeat.com&utm_medium=referral
No. 1 stock to cash in on the death of iPhone
Analyst Josh Baylin, who warned Congress about smartphones years before the iPhone launched, says the world's richest man may be building an iPhone rival he calls Starphone. Baylin points to FCC rulings, two trademarks filed the same day, multibillion-dollar spectrum deals, chip partnerships, and a string of posts from Elon Musk as evidence pointing to one conclusion. See the full research and the stock Baylin is watching now.tc pixel
 |  Stansberry Research (Ad)
What to Expect From Incyte’s Next Quarterly Earnings Report
October 9 at 6:50 AM  |  barchart.comhttps://www.barchart.com/story/news/5298940/what-to-expect-from-incytes-next-quarterly-earnings-report
Incyte to Report Third Quarter Financial Results
October 8 at 2:25 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/incyte-report-third-quarter-financial-120000141.html
Knight Therapeutics Announces Regulatory Approval of NIKTIMVO® in Brazil
October 6, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/06/3375375/0/en/knight-therapeutics-announces-regulatory-approval-of-niktimvo-in-brazil.html
See More Incyte Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Incyte? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Incyte and other key companies, straight to your email.

About Incyte

Incyte (NASDAQ:INCY) is a biopharmaceutical company focused on discovering, developing and commercializing medicines for serious diseases, with an emphasis on oncology, hematology and inflammatory or dermatologic conditions. The company conducts research through internal programs and collaborations with academic institutions, biotechnology companies and pharmaceutical partners.

Incyte’s marketed portfolio includes Jakafi (ruxolitinib), a JAK inhibitor used in the United States for certain myelofibrosis, polycythemia vera and graft-versus-host disease indications, and Opzelura (ruxolitinib) cream for certain inflammatory skin conditions. Its portfolio also includes Pemazyre (pemigatinib), a targeted therapy for selected cancers with specific fibroblast growth factor receptor alterations. Incyte continues to develop additional therapies in oncology, immunology and dermatology.

Founded in 1991, Incyte is headquartered in Wilmington, Delaware, and serves patients in the United States and international markets through its own commercial operations and partnerships. The company’s products may be marketed under different brand names or by collaborators outside the United States. Incyte is led by President and Chief Executive Officer Hervé Hoppenot.

View Incyte Profile
Earnings Tools